A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (NCT07412756)

Eli Lilly GZMH

This trial is Currently recruiting
Registration number NCT07412756
A phase 3 Clinical Trial investigating the effectiveness of a GLP-1 drug in preventing or delaying relapse in MDD

Program & service

This trial is being run with the Brain service, and as part of the MAPrc program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Rebecca Ho

Key inclusion data

Aged 18-75 BMI >22 Not currently in a depressive episode Experienced 3+ depressive episodes in the past Currently on a stable antidepressant dose for 8+ weeks

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.